| Age | Recommended for children 2 to 10 years who have a history of Guillain-Barré syndrome and who desire immunization | Recommended for all children 11 to 12 years of age, unvaccinated children entering high school, college freshmen living in dormitories, and military recruits |
| | Recommended for children 2 to 10 years of age who need to be vaccinated because of risk factors or travel |
| | May be given three years after MPSV4 is administered |
| Preservative | Thimerosal | None |
| Revaccination | If at risk, revaccinate five years after the first dose, but use MCV4 | Revaccination not recommended |
| Route of administration | Subcutaneously | Intramuscularly |
| Side effects | Mild adverse reactions, including fever, occur in up to 3 percent of children45 | Mild adverse reactions, including fever, occur in up to 3 percent of children |
| Special considerations | May be used in persons 11 to 55 years if MCV4 is not available | May be used in persons 11 to 55 years who are at risk of invasive meningococcal disease |
| Vaccine components | Quadrivalent polysaccharide vaccine (serotypes A, C, Y, W-135) | Quadrivalent polysaccharide vaccine (serotypes A, C, Y, W-135) conjugated to diphtheria toxin |